# A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT02457793** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** GDC-0994

## Key facts

- **NCT ID:** NCT02457793
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-16
- **Primary completion:** 2016-12-05
- **Final completion:** 2016-12-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02457793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02457793, "A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02457793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*